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Abstract
Background: Dengue is the most common mosquito-borne viral disease in humans. Recently, there has been an
epidemic shift of dengue from mainly affecting children to affecting more adults with increased severity. However,
clinical factors associated with severe dengue in adults have varied widely between studies. We aimed to identify
the clinical factors associated with the development of severe dengue according to the World Health Organization
(WHO)’s 2009 definition.
Methods: We conducted a prospective study of adults with dengue admitted to the Hospital for Tropical Diseases
in Bangkok, Thailand, from October 2012 to December 2014. Univariate and stepwise multivariate logistic regression
analyses were performed.
Results: Of the 153 hospitalized patients with confirmed dengue viral infections, 132 (86.3 %) patients had non-severe
dengue including dengue without warning signs (7 patients, 5.3 %) and dengue with warning signs (125, 94.7 %). The
rest (21, 13.7 %) had severe dengue including severe plasma leakage (16, 76.2 %), severe organ involvement (16, 76.2 %),
and severe clinical bleeding (8, 38.1 %). Using stepwise multivariate logistic regression, clinical factors identified
as independently associated with the development of severe dengue were: (1) being >40 years old (odds ratio [OR]:
5.215, 95 % confidence interval [CI]: 1.538–17.689), (2) having persistent vomiting (OR: 4.817, CI: 1.375–16.873),
(3) having >300 cells per μL of absolute atypical lymphocytes (OR: 3.163, CI: 1.017–9.834), and (4) having lactate levels
≥2.0 mmol/L (OR: 7.340, CI: 2.334–23.087). In addition, increases in lactate and absolute atypical lymphocyte levels
corresponded with severe dengue (p < 0.05).
Conclusions: Our study identified several clinical factors independently associated with the development of severe
dengue among hospitalized adults with dengue. This can aid in the early recognition and prompt management
of at-risk patients to reduce morbidity and mortality.
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Background
Dengue is caused by four dengue virus serotypes
(DENV 1–4) and it is the most rapidly spreading
mosquito-borne viral disease in humans [1]. Annually,
approximately 50–100,000 000 people contract dengue
viral infections worldwide and an estimated 500,000
people with dengue hemorrhagic fever (DHF) require
hospitalization [2]. The mortality rate of dengue is
approximately 20,000 deaths per year with a morbid-
ity of 264 disability-adjusted life years per million
people per year [1]. During the past decades, the emer-
gence of dengue has been reported throughout the world
with a 30-fold increase in global incidence and severity. Ap-
proximately 75 % of the global populations exposed to den-
gue reside in the Asia-Pacific region [1].
Previous reports have shown an epidemic shift of den-
gue from mainly affecting children to now affecting
more adults [2–4]. Children and adults with dengue
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differ in both clinical manifestations and laboratory find-
ings [5, 6], and the incidence of “severe dengue” accord-
ing to the WHO's 2009 definition has increased among
adults [2, 7]. In 2009, the WHO introduced a new den-
gue case definition to emphasize clinical management
and to increase the sensitivity and specificity of severe-
dengue diagnosis [8]. A recent systemic review of the
application of the WHO’s 2009 definition showed a sen-
sitivity of 59–98 % and a specificity of 41–99 % for iden-
tifying severe dengue [9].
In Thailand, the number of adults with dengue has in-
creased dramatically in recent decades [1, 4]. According
to the WHO’s 2009 definition, approximately 27.9 % of
hospitalized Thai adults with dengue had severe dengue
from 2006 to 2010 [10]. Although several studies have
been conducted, the clinical factors associated with se-
vere dengue in adults have varied widely due to (1) the
differences in applying the definitions of severe dengue,
by using either the WHO’s 1997 definition or the
WHO’s 2009 definition, (2) differences in the study de-
signs, and (3) differences in the data analyses [10–14].
Thus, these studies have reported widely varying re-
sults of the clinical factors associated with severe
dengue, including having secondary dengue infections,
age >37 years, male gender, presence of intense asthe-
nia, presence of abdominal pain, presence of cough,
presence of bleeding, a mean arterial pressure (MAP)
less than 80 mmHg, an increase in hematocrit levels
to more than 2 % over the reference range (adjusted for
gender), low lymphocyte level, higher aspartate amino-
transferase (AST) or alanine aminotransferase (ALT)
levels by more than 3 times, and low total protein level
[10–14]. Currently, the WHO’s 2009 definition has been
widely used for the diagnosis of severe dengue [8, 9].
Therefore, we conducted a prospective study among
adults admitted to the hospital with dengue in order to
determine the clinical factors associated with the develop-
ment of severe dengue using the WHO’s 2009 definition.
Methods
Study design and population
This prospective study was conducted at the Hospital for
Tropical Diseases, Faculty of Tropical Medicine, Mahidol
University in Bangkok, Thailand. Patients admitted to the
hospital between October 2012 and December 2014 who
met the study criteria were approached for participation.
The study’s inclusion criteria were: (1) adults at least
15 years old; (2) presenting with clinical criteria for dengue
defined as acute fever with at least two of the following
symptoms: headache, retro-orbital or ocular pain, myalgia,
arthralgia, rash, a positive tourniquet test (defined as the
presence of ≥20 petechiae per 1 square inch), or leukopenia
(defined as a white blood cell count [WBC] <5.0 × 103 cells
per μL); and (3) having a confirmed dengue viral infection,
defined as positive tests of either (a) viral nucleic acid using
reverse-transcriptase polymerase chain reaction (RT-PCR)
from serum samples on admission or (b) specific dengue
IgM and IgG antibodies using enzyme-linked immunosorb-
ent assays (ELISA) from serum samples on admission and
at least two weeks later. Patients with a history of under-
lying medical illness or mixed infection, or who were preg-
nant, were excluded from this study.
The laboratory investigations including complete blood
count, blood chemistries, and peripheral venous lactate
were performed at patient admission. All dengue patients
in this study received standard care according to WHO
guidelines [8]. Patient data including baseline characteris-
tics, clinical parameters, and laboratory findings were re-
corded in a pre-defined case-report form. Severity of
dengue was summarized on the date of discharge accord-
ing to the WHO’s 2009 definition [8].
Case definition of dengue
According to the WHO’s 2009 dengue case definition
[8], dengue patients were classified into non-severe den-
gue and severe dengue based on clinical and laboratory
criteria. Patients with non-severe dengue were sub-
categorized into two groups depending on the presence
or absence of warning signs. Non-severe dengue without
warning signs was defined as having acute fever with at
least two of the following criteria: nausea, vomiting,
rash, myalgia, arthralgia, a positive tourniquet test, or
leukopenia. Warning signs included: (1) abdominal pain,
(2) persistent vomiting (vomiting with signs of dehy-
dration), (3) clinical fluid accumulation, (4) lethargy,
(5) liver span >15 cm, (6) bleeding from mucosal
areas including nose, gums, gastrointestinal tract or
vagina, or (7) an elevated hematocrit, >2 % above the
reference range for a healthy Thai adult adjusted for
gender with platelet counts ≤100 × 103 per μL. Severe
dengue was classified as having: (1) severe plasma
leakage, defined as plasma leakage with shock or respira-
tory distress (respiratory rate ≥24 breaths/min with oxy-
gen saturation <95 % in room air and/or requiring oxygen
therapy), (2) severe clinical bleeding, defined as spontan-
eous bleeding from mucosal areas that necessitates a
blood transfusion or bleeding in vital organs, (3) severe
organ involvement, defined as AST >1000 IU/L and/or
ALT >1000 IU/L, serum creatinine ≥3 times above base-
line, myocarditis, and/or encephalitis.
Reverse-transcriptase Polymerase Chain Reaction (RT-PCR)
Dengue viral RNA in patient sera was extracted using
two rounds of PCR as described by Lanciotti et al. [15]
with modifications according to Reynes et al. [16]. Sam-
ples were extracted using a PureLink® Viral RNA/DNA
Mini Kit (Invitrogen™, USA) according to the manufac-
turer’s instructions.
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Serology for dengue viral infection
All sera were tested with four separate assays of IgM
and IgG antibodies for dengue viruses and Japanese en-
cephalitis virus (JEV) using capture ELISA as described
by Innis et al. [17]. In order to differentiate dengue viral
infections from other flavivirus infections, the ratio of
dengue IgM to JEV IgM was calculated. A ratio ≥1.0 was
defined as dengue virus infection whereas a ratio <1.0
was defined as other flavivirus infection. To assess
primary and secondary dengue infections, the ratio of
dengue IgM to dengue IgG was calculated. A ratio ≥1.8
was considered a primary dengue infection whereas a
ratio <1.8 was considered to indicate a secondary dengue
infection.
Measurement of peripheral venous lactate
Blood samples for peripheral venous lactate were col-
lected from veins of upper extremities without the use
of a tourniquet. We placed 2 ml of blood in a vacutainer
containing sodium fluoride and immediately placed the
sample on ice. Samples were sent to the laboratory and
lactate levels were tested within 10 min of being drawn
using a colorimetric assay (Roche/Hitashi cobas c sys-
tems, USA) according to the manufacturer’s instructions.
The coefficient of variation in lactate assay levels in the
central laboratory of the Hospital for Tropical Diseases
is estimated to be 1.1 %.
Sample-size calculation
We estimated the required sample size for each po-
tentially associated factor and used the highest esti-
mated number. The required sample size for this
study was estimated using the Power and Sample
Size Program, version 3.0, 2009 [18]. Based on our
previous study, the rate of developing severe dengue
among hospitalized adults with dengue who had
MAP ≥80 mmHg was 0.25 [10]. If the true relative
risk of developing severe dengue among patients
with MAP <80 mmHg was double that of patients
with MAP ≥80 mmHg then the study required a 1:2
ratio of patients with MAP <80 mmHg to patients
MAP ≥80 mmHg. We needed to study 48 patients with
MAP <80 mmHg and 96 patients with MAP ≥80 mmHg
to be able to reject the null hypothesis that the rela-
tive risk between these groups was equal to 1 with
probability (power) of 0.85. The type I error probabil-
ity associated with this test was 0.05. Thus, we
needed to study a minimum of 144 patients with
dengue.
Statistical analyses
Data were analyzed using SPSS for Windows 18.0 (IBM
Corp., Chicago, IL). Numerical variables were tested for
normality using Kolmogorov-Smirnov tests. Variables
with non-normal distributions were summarized with
medians and inter-quartile ranges (IQR) and compared
using Mann–Whitney U tests. Categorical variables were
expressed as frequencies and percentages and then ana-
lyzed with chi-square tests or Fisher’s exact tests, as ap-
propriate. A univariate logistic regression was performed
with each potential factor included as an independent
variable and the presence or absence of severe dengue
infection as the dependent variable. Any variable with a
p-value less than 0.2 was considered potentially signifi-
cant and then further analyzed in a stepwise multivariate
logistic regression using the backward selection method
for determining significant independent factors. All tests
of significance were two-sided with p < 0.05 indicating
statistical significance.
Ethics statement
This study was approved by the Ethics Committee of the
Faculty of Tropical Medicine, Mahidol University,
Bangkok, Thailand. The procedure indicated by the
Standards for the Reporting of Observation Studies in
Epidemiology (STROBE) was followed [19]. Written in-
formed consent was obtained from all the patients or
the patients’ guardians in cases where the patients were
less than 18 years of age. Data were made anonymous
before analyses.
Results
From October 2012 to December 2014, there were 236
patients admitted to the Hospital for Tropical Diseases
in Bangkok, Thailand, with suspected dengue infections.
Of these, 83 patients were excluded from our study be-
cause they had a mixed infection (41 patients), a history
of underlying medical illness (32 patients), or negative
results for dengue in their RT-PCR and IgM/IgG anti-
body tests (10 patients). Thus, a total of 153 hospitalized
patients with confirmed dengue viral infections were
recruited to the study. Among these participants, den-
gue serotypes were identified using RT-PCR in 88
(57.5 %) patients, indicating DENV 1 (3 patients, 3.4 %),
DENV 2 (9, 10.2 %), DENV 3 (50, 56.8 %), and DENV 4
(26, 29.5 %). Dengue IgM/IgG antibodies were detected by
ELISA in 144 patients (94.1 %) indicating a primary den-
gue infection in 5 patients (3.5 %) and secondary dengue
infection in 139 patients (96.5 %; see Fig. 1).
Of the 153 patients with a confirmed dengue infection,
132 (86.3 %) had non-severe dengue including dengue
without warning signs (7 patients, 5.3 %) and dengue with
warning signs (125 patients, 94.7 %). The remaining 21 pa-
tients (13.7 %) had severe dengue. Of the 21 patients with
severe dengue, 16 (76.2 %) had severe plasma leakage, 16
(76.2 %) had severe organ involvement, and 8 (38.1 %) had
severe clinical bleeding. Of the 16 patients with severe
plasma leakage, 12 (75.0 %) had plasma leakage with
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shock and 8 (50.0 %) had plasma leakage with re-
spiratory distress. Of the 16 patients with severe
organ involvement, 9 (56.2 %) had AST >1000 IU/L
and/or ALT >1000 IU/L, 9 (56.2 %) had serum creatinine
≥3 times above baseline, 1 (6.2 %) had myocarditis, and 1
(6.2 %) had encephalitis.
Comparison between patients with severe and
non-severe dengue
Regarding the baseline characteristics of study patients,
the development of severe dengue was significantly asso-
ciated with (1) patient age being >40 years (9 [42.9 %]
patients with severe dengue vs. 19 [14.4 %] patients with
non-severe dengue; p = 0.004) and (2) patients receiving
nonsteroidal anti-inflammatory drugs (NSAIDs) or cy-
clooxygenase II (COX II) inhibitors before admission
(6 [28.6 %] patients with severe dengue vs. 13 [9.8 %]
patients with non-severe dengue; p = 0.027). Other pa-
tient characteristics such as gender, residential area,
and receiving acetaminophen before admission were
similar between patients with severe and non-severe
dengue (see Table 1).
The majority of symptoms at admission were similar
between patients with severe and non-severe dengue
with the following exceptions, which were more frequent
among patients with severe dengue than those with
non-severe dengue (see Table 1): (1) mucosal bleeding
(14 [66.7 %] patients with severe dengue vs. 48
[36.4 %] patients with non-severe dengue; p = 0.017),
(2) skin bleeding (13 [61.9 %] patients with severe
dengue vs. 28 [21.2 %] patients with non-severe dengue;
p < 0.001), (3) liver span >15 cm (12 [57.1 %] patients
with severe dengue vs. 19 [14.4 %] patients with non-
severe dengue; p < 0.001), (4) decreased sound breathing
(11 [52.4 %] patients with severe dengue vs. 6 [4.5 %]
patients with non-severe dengue, p < 0.001), and (5) per-
sistent vomiting (9 [42.9 %] patients with severe dengue
vs. 15 [11.4 %] patients with non-severe dengue; p =
0.001).
Laboratory findings of patients at admission are shown in
Table 2. Most laboratory results among patients with
severe and non-severe dengue were similar with the
exceptions of platelet counts and albumin, which were
both significantly lower among patients with severe
dengue compared to those with non-severe dengue
(p < 0.001). However, patients with severe dengue had sig-
nificantly greater: WBC (p = 0.034), absolute atypical
lymphocyte count (p = 0.011), lactate level (p < 0.001),
AST level (p < 0.001), and ALT level (p = 0.003). When pa-
tients were categorized based on the upper or lower limits
of the reference ranges, patients with severe dengue were
significantly more likely to fall into the following cat-
egories: absolute lymphocyte count >2000 cells per μL
(p = 0.036), absolute atypical lymphocyte count >300
cells per μL (p = 0.002), platelet count ≤100 × 103 per μL
(p = 0.031), lactate level ≥2.0 mmol/L (p < 0.001), albu-
min level <3.5 g/dL (p < 0.001), AST level >120 IU/L
(p = 0.017), and ALT level >120 IU/L (p = 0.032). The
median (IQR) duration of hospitalization among pa-
tients with severe dengue were significantly longer
than those with non-severe dengue (4.8 [2.9–9.8] vs.
3.7 [2.7–4.8] days; p = 0.047).
Univariate and multivariate analyses for development of
severe dengue
A univariate logistic regression analysis was used to de-
termine which of the baseline characteristics, clinical pa-
rameters, and laboratory findings may be associated
with the development of severe dengue. All clinical
factors potentially associated with the development
Fig. 1 Flow diagram for recruitment and assessment of study patients
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of severe dengue were included in the univariate lo-
gistic regression analysis. We identified the following
clinical factors associated with severe dengue: (1) age
>40 years, (2) receiving NSAIDs or COX II inhibi-
tors before admission, (3) persistent vomiting, (4) ab-
solute lymphocytes >2000 cells per μL, (5) absolute
atypical lymphocytes >300 cells per μL, and (6) lactate
level ≥2.0 mmol/L (Table 3).
All parameters with p ≤ 0.2 in the univariate logistic
regression analysis were then further analyzed by a step-
wise multiple logistic regression using the backward se-
lection method in order to determine the independent
clinical factors significantly associated with the develop-
ment of severe dengue. We found the following clinical
and laboratory findings to be independently associated
with the development of severe dengue: (1) age >40 years
(odds ratio [OR]: 5.215; CI: 1.538–17.689; p = 0.008),
(2) persistent vomiting (OR: 4.817, CI: 1.375–16.873;
p = 0.014), (3) absolute atypical lymphocyte >300 cells
per μL (OR: 3.163, CI: 1.017–9.834; p = 0.047), and
(4) lactate level ≥2.0 mmol/L (OR: 7.340, CI: 2.334–
23.087; p = 0.001) (Table 3).
Lactate level and absolute atypical lymphocytes by
dengue severity
The median (IQR) lactate levels in patients with dengue
are shown in Fig. 2. The level of lactate among patients
with severe dengue was significantly greater than pa-
tients with non-severe dengue (p < 0.05) and the extent
of elevated lactate was associated with severity of den-
gue. Similarly, atypical lymphocyte count also increased
with severity of dengue (Fig. 3) and patients with severe
dengue had significantly higher levels of atypical lym-
phocytes than those with non-severe dengue with warn-
ing signs (p = 0.016).
Discussion
Dengue is the most common mosquito-borne viral
disease in humans and it is a significant public health
problem, particularly in Asian-Pacific regions like
Thailand [1]. Previous reports have shown that both
the number of adults infected with dengue and its se-
verity have increased dramatically in recent decades
[2, 4–7] and the clinical factors associated with severe
dengue in adults have varied widely between studies
[10–14]. We therefore conducted a prospective study
among Thai adults admitted to the hospital with den-
gue in order to identify the clinical factors associated
with severe dengue according to the WHO’s 2009
definition, which would help improve the diagnostic
process of severe dengue.
The majority of hospitalized adults with dengue had a
secondary dengue infection. We found no association
between secondary infection and the development of
Table 1 Patient characteristics. Baseline characteristics and clinical
parameters at admission of 153 hospitalized adults with either severe




dengue (n = 132)
p-value
# (%) # (%)
Baseline characteristics
Age 0.004
≤ 40 years 12 (57.1) 113 (85.6)
> 40 years 9 (42.9) 19 (14.4)
Gender 0.771
Male 10 (47.6) 71 (53.8)
Female 11 (52.4) 61 (46.2)
Residential area 1.000
Bangkok 18 (85.7) 109 (82.6)
Outside Bangkok 3 (14.3) 23 (17.4)
Medication before
admission
Acetaminophen 20 (95.2) 123 (93.2) 1.000





37.8 (37.0–39.0) 38.4 (37.8–39.2) 0.162
HR, median (IQR), beats/
min
82 (68–90) 79 (66–88) 0.176
MAP, median (IQR), mmHg 83 (70–92) 86 (78–92) 0.561
PP, median (IQR), mmHg 32 (26–45) 38 (33–45) 0.058
History and physical
examinations
Myalgia 20 (95.2) 120 (90.9) 1.000
Lethargy 19 (90.5) 101 (76.5) 0.251
Headache 18 (87.5) 113 (85.6) 1.000
Fever ≥4 days 17 (81.0) 84 (63.6) 0.191
Tourniquet test positive 16 (76.2) 111 (84.1) 0.359
RR ≥24 breaths/min 15 (71.4) 112 (84.8) 0.206
Mucosal bleeding 14 (66.7) 48 (36.4) 0.017
Skin bleeding 13 (61.9) 28 (21.2) <0.001
Liver span > 15 cm 12 (57.1) 19 (14.4) <0.001
Retro-orbital pain 11 (52.4) 90 (68.2) 0.241
Decrease breath sound 11 (52.4) 6 (4.5) <0.001
Arthralgia 10 (47.6) 37 (28.0) 0.120
Rash 10 (47.6) 61 (46.2) 1.000
Abdominal pain 9 (42.9) 53 (40.2) 1.000
Persistent vomiting 9 (42.9) 15 (11.4) 0.001
Diarrhea 5 (23.8) 44 (33.3) 0.537
Abbreviations: NSAIDs nonsteroidal anti-inflammatory drugs, COX II cyclooxygenase
II, IQR interquartile range, HR heart rate, MAP mean arterial pressure, PP pulse
pressure, RR respiratory rate
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Table 2 Laboratory test results. Laboratory parameters on admission of 153 hospitalized adults with dengue by dengue severity
according to the WHO’s 2009 definition
Characteristics Severe dengue (n = 21) Non-severe dengue (n = 132) p-value
# (%) # (%)
Confirmation tests for dengue
Known dengue RT-PCR (n = 88) 0.765
Serotypes 1 or 4 4 (19.0) 25 (18.9)
Serotypes 2 or 3 11 (52.4) 48 (36.4)
Known serological response to infection (n = 144) 0.551
Primary dengue infection 1 (4.8) 4 (3.0)
Secondary dengue infection 20 (95.2) 119 (90.2)
Complete blood counts
Hemoglobin, median (IQR), g/dL 14.0 (12.5–16.6) 13.8 (12.8–14.9) 0.627
Hematocrit, median (IQR), % 41.7 (36.7–48.5) 41.1 (38.3–44.4) 0.934
WBC, median (IQR), ×103 cells per μL 4.7 (2.4–10.5) 3.1 (2.3–4.6) 0.034
Absolute band form, median (IQR), cells per μL 188 (87–372) 142 (60–666) 0.237
Absolute PMN, median (IQR), cells per μL 2320 (1210–4126) 1620 (873–2264) 0.055
Absolute LYM, median (IQR), cells per μL 940 (405–2011) 758 (546–1126) 0.509
Absolute ALYM, median (IQR), cells per μL 684 (108–1370) 138 (68–379) 0.011
Platelet counts, median (IQR) × 103 per μL 56.0 (12.0–71.0) 85.0 (56.0–136.2) <0.001
Categorical data
Hematocrit 0.928
≤ 2 % above reference range 7 (33.3) 49 (37.1)
> 2 % above reference range 14 (66.7) 83 (62.9)
Absolute band form 1.000
≤ 250 cells per μL 15 (71.4) 97 (73.5)
> 250 cells per μL 6 (28.6) 35 (26.5)
Absolute PMN 0.422
< 1500 cells per μL 7 (33.3) 60 (45.5)
≥ 1500 cells per μL 14 (66.7) 72 (54.5)
Absolute LYM 0.036
≤ 2000 cells per μL 16 (76.2) 122 (92.4)
> 2000 cells per μL 5 (23.8) 10 (7.6)
Absolute ALYM 0.002
≤ 300 cells per μL 8 (38.1) 99 (75.0)
> 300 cells per μL 13 (61.9) 33 (25.0)
Platelet counts 0.031
≤ 100 × 103 per μL 18 (85.7) 77 (58.3)
> 100 × 103 per μL 3 (14.3) 55 (41.7)
Blood chemistries
Creatinine, median (IQR), mg/dL 0.8 (0.6–1.1) 0.8 (0.6–1.0) 0.739
Lactate level, median (IQR), mmol/L 2.7 (1.7–3.1) 1.4 (1.2–1.8) <0.001
Albumin, median (IQR), g/dL 3.7 (3.2–4.3) 4.3 (4.0–4.5) <0.001
AST, median (IQR), IU/L 219 (94–692) 76 (37–158) <0.001
ALT, median (IQR), IU/L 100 (61–346) 47 (18–106) 0.003
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severe dengue, consistent with previous studies [20, 21].
However, a number of reports showed that the second-
ary dengue infection was associated with severe dengue
[11, 13, 22]. Furthermore, in contrast to previous studies
showing that DENV 2 and DENV 3 were associated with
the occurrence of severe dengue [23, 24], we found no
association between dengue serotypes and disease sever-
ity. Indeed, a recent study from Thailand showed that,
rather than dengue serotypes, a longer period of time
between sequential DENV infections was associated with
Table 2 Laboratory test results. Laboratory parameters on admission of 153 hospitalized adults with dengue by dengue severity
according to the WHO’s 2009 definition (Continued)
Categorical data
Lactate level <0.001
< 2.0 mmol/L 7 (33.3) 111 (84.1)
≥ 2.0 mmol/L 14 (66.7) 21 (15.9)
Albumin <0.001
< 3.5 g/dL 13 (61.9) 128 (97.0)
≥ 3.5 g/dL 8 (38.1) 4 (3.0)
AST 0.017
≤ 120 IU/L 7 (33.3) 84 (63.6)
> 120 IU/L 14 (66.7) 48 (36.4)
ALT 0.032
≤ 120 IU/L 11 (52.4) 102 (77.3)
> 120 IU/L 10 (47.6) 30 (22.7)
Abbreviations: RT-PCR reverse-transcriptase polymerase chain reaction, IQR interquartile range, WBC white blood cell counts, PMN neutrophils, LYM lymphocytes,
ALYM atypical lymphocytes, AST aspartate aminotranferase, ALT alanine aminotransferase
Table 3 Regression analyses. Univariate and multivariate logistic regression analysis of baseline characteristic, clinical and laboratory
parameters for development of severe dengue according to the WHO’s 2009 definition among 153 hospitalized adults with dengue
Characteristics Univariate logistic regression analysis Multivariate logistic regression analysis
Odds ratio (95 % CI) p-value Odds ratio (95 % CI) p-value
Age
≤ 40 years 1.000 (Reference) 1.000 (Reference)
> 40 years 4.461 (1.655–12.023) 0.003 5.215 (1.538–17.689) 0.008
NSAIDs or COX II inhibitors
No 1.000 (Reference)
Yes 3.662 (1.211–11.070) 0.021
Persistent vomiting
No 1.000 (Reference) 1.000 (Reference)
Yes 5.850 (2.114–16.187) 0.001 4.817 (1.375–16.873) 0.014
Absolute lymphocytes
≤ 2000 cells per μL 1.000 (Reference)
> 2000 cells per μL 3.812 (1.156–12.574) 0.028
Absolute atypical lymphocytes
≤ 300 cells per μL 1.000 (Reference) 1.000 (Reference)
> 300 cells per μL 4.875 (1.858–12.794) 0.001 3.163 (1.017–9.834) 0.047
Lactate level
< 2.0 mmol/L 1.000 (Reference) 1.000 (Reference)
≥ 2.0 mmol/L 10.571 (3.811–29.321) <0.001 7.340 (2.334–23.087) 0.001
Abbreviations: CI confidence interval, NSAIDs nonsteroidal anti-inflammatory drugs, COX II cyclooxygenase II
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more severe infections, a finding supported by the role
of heterotypic immunity in either protection or enhance-
ment of the infection [25].
With regard to the WHO’s 2009 guidelines for the
management of dengue, patients with warning signs who
develop high fever should be administered acetamino-
phen along with tepid sponge application for reducing
the fever; however, NSAIDs should be avoided as these
drugs may aggravate the complications, particularly
gastrointestinal tract bleeding [8]. At present, it is well
established that the use of NSAIDs increase the risk of
gastrointestinal, renal, and cardiovascular side effects
[26, 27]. COX II inhibitors have been shown to reduce
gastrointestinal side effects, although cardiovascular and
renal side effects still develop [27, 28]. A previous report
from the Philippines showed that, of 24 American mili-
tary personnel who were hospitalized with dengue, 1 de-
veloped dengue shock syndrome and had upper
gastrointestinal bleeding; however, this patient most
likely had a history of aspirin use [29]. However, a recent
study showed that aspirin could suppress flavivirus repli-
cation [30]. Our univariate analysis indicated that pa-
tients who received NSAIDs or COX II inhibitors were
more likely to develop severe dengue, but that the use of
NSAIDs or COX II inhibitors was not independently as-
sociated with the development of severe dengue.
In our study, multivariate regression indicated the fol-
lowing clinical and laboratory characteristics upon admis-
sion were independently associated with the development
of severe dengue: (1) age >40 years, (2) persistent
vomiting, (3) absolute atypical lymphocyte >300 cells
per μL, and (4) lactate level ≥2.0 mmol/L. In addition,
patients with severe dengue commonly presented with
severe plasma leakage and severe organ involvement.
Age >40 years was independently associated with se-
vere dengue in our study, consistent with a previous
retrospective analysis from France, which reported
that plasma leakage was the most common presentation
for adults with severe dengue and that an age of >37 years
predicted plasma leakage [14]. Our results also suggest
that persistent vomiting at admission could be used to
predict the development of severe dengue, which is similar
to a finding of a previous multicenter study showing that
persistent vomiting was one of the warning signs for
severe dengue [31]. Although the sensitivity of persist-
ent vomiting for identifying severe dengue in adults
was very low (6.0–23.0 %), the specificity was as high
as 93.0–96.0 % and the negative predictive value was
82.0–97.0 % [32, 33].
Regarding laboratory findings on admission, patients
having >300 cells/μL of absolute atypical lymphocytes
could be used to predict the development of severe
Fig. 2 Lactate levels at admission. Distribution of lactate levels at
admission of 153 hospitalized adults with severe dengue and
non-severe dengue with and without warning signs (according
to the WHO’s 2009 definition). Non-severe dengue without warning
signs was not significantly different than non-severe with warning
signs (p = 0.490). Severe dengue was significantly different than both
non-severe with warning signs (p < 0.001) and non-severe without
warning signs (p = 0.006)
Fig. 3 Absolute atypical lymphocyte levels. Distribution of absolute
atypical lymphocytes among 153 hospitalized adults with severe
dengue and non-severe dengue with and without warning signs
(according to the WHO’s 2009 definition). Non-severe dengue
without warning signs was not significantly different than non-severe
with warning signs (p = 0.859). Severe dengue was significantly
different than non-severe with warning signs (p = 0.016), but not
non-severe without warning signs (p = 0.533)
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dengue as patients with severe dengue had significantly
greater levels of absolute atypical lymphocytes than pa-
tients with non-severe dengue. These findings are similar
to those of a previous Thai study showing that atypical
lymphocytes among patients with dengue were corre-
lated with the presence of CD19 + B lymphocytes [34].
After a secondary dengue infection, atypical lymphocytes
could indicate an augmented immune response attempt-
ing to control the spread of dengue-infected cells [35].
Simultaneously, these antibodies could enhance the
entry of the dengue virus into macrophages and den-
dritic cells whereupon the virus would replicate [36].
Previous reports have also indicated that patients with
higher dengue viremia have higher disease severity [37].
In addition, patients having lactate levels ≥2.0 mmol/L
could be used as a predictor of the development of se-
vere dengue as elevated lactate levels was observed to
correspond to dengue severity in our study. Currently,
lactate is used as a biomarker for severity of systemic hy-
poperfusion or impaired microcirculatory perfusion re-
gardless of organ failure and shock [38]. One previous
report has also indicated that elevated arterial or central
venous lactate levels could be used to predict in-hospital
mortality associated with many conditions such as infec-
tion or sepsis, liver disease, trauma, or cardiac arrest
[39]. However, the arterial or central venous sampling
required to measure lactate concentration is invasive
and may increase risk of bleeding in patients with
dengue. One previous study has shown a strong correl-
ation between arterial and peripheral venous lactate
levels (r2 = 0.89) [40], and so we used peripheral venous
sampling for lactate concentration. We found that the
presence of peripheral venous lactate ≥2.0 mmol/L at
admission was independently associated with severe
dengue. This finding is similar to that of a previous
study among children with dengue [41]. We also show
that peripheral venous lactate levels at admission are
associated with increasing dengue severity in a dose-
dependent manner. MAP and pulse pressure at admis-
sion were not significantly different among patients with
severe and non-severe dengue. Previous studies have
suggested that microvascular leakage occurs among pa-
tients with severe dengue leading to systemic hypoperfu-
sion or impaired microcirculatory perfusion that can
progress to shock [36, 42, 43]. These studies have sug-
gested that systemic hypoperfusion or impaired micro-
circulatory perfusion in dengue probably occur prior to
decreases in blood pressure and other hemodynamic pa-
rameters. Another possibility is that blood pressure and
pulse pressure are insensitive hemodynamic parameters
for identifying systemic hypoperfusion or microcirculatory
failure among patients with dengue. In our study, lactate
levels at admission could be used as a predictor for the se-
verity of dengue. However, further studies are essential to
assess the performance of lactate level as a diagnostic bio-
marker and/or its combination with other associated clin-
ical factors for identifying severe dengue.
Our study has some limitations: (1) we recruited pa-
tients from only a single center in Thailand and our data
may not be representative of dengue patients elsewhere,
(2) only hospitalized patients were recruited to this study
and we included few patients with non-severe dengue
without warning signs, and (3) patients were admitted to
the hospital at different times following the onset of fever
and so the exact time of elevated level of lactate in pa-
tients with severe dengue could not be determined.
Conclusions
Our findings indicate that age (>40 years), persistent
vomiting, absolute atypical lymphocytes (>300 cells
per μL), and lactate level (≥2.0 mmol/L) at admission
could be used to identify those individuals at greatest
risk of developing severe dengue. Early recognition and
prompt management of adults with severe dengue might
help to reduce morbidity and mortality in future.
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